Trial Profile
Study to evaluate the Hepatotoxicity and its outcomes after Pembrolizumab Immunotherapy in cancer patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2019
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 15 Jul 2019 Results describing the incidence, phenotypes and outcomes of liver injury in a large cohort of solid organ tumour patients published in the Alimentary Pharmacology and Therapeutics
- 14 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases